MSD has been rocked by a court judgment ordering it to stop manufacturing and selling its subcutaneous formulation of cancer ...

Novartis' oral BTK inhibitor Rhapsido has had its label expanded in the US to include ​a second indication, symptomatic ...

A survey of senior figures in European biopharma companies has found that dealmaking and M&A are expected to increase, with ...

Klick Health's recent acquisition of Oxford PharmaGenesis reflects that shift. “Clearly for a lot of reasons that have been ...

Novartis has a much-anticipated approval for its spinal muscular atrophy (SMA) treatment onasemnogene abeparvovec in the US, getting a green light for a new version that can make more patients ...

Wegovy has since been joined in the UK market by Eli Lilly's oral GLP-1 agonist Foundayo (orforglipron), which was approved by the MHRA in August. Neither product is covered by the NHS, but can be ...

Click Therapeutics has won the first-ever FDA approval for a treatment for the negative symptoms of schizophrenia – a digital ...

The governor of New York has said that rising cases of measles constitute a "statewide disaster emergency," the first such ...

As antibody-drug conjugates (ADCs) continue to establish themselves as a cornerstone of modern oncology, breakthrough ...

This is not simply a broader role for Market Access. It is an emerging leadership capability for the healthcare business.

Day One Strategy’s second annual AI in Pharma State of Play report – Are Insights leaders seeing real commercial value from AI adoption yet? – addresses the challenges Pharma Insights teams are facing ...

AstraZeneca's pivot towards the US market has continued with the opening of a new R&D centre in the biotech hotspot of ...